Therapeutic SINERGY for modulation of gut inflammation and microbiome in DSS-induced colitis
We evaluated the therapeutic capacity of engineered SINERGY consortia, consisting of the eATP sensor S. cerevisiae strain (Design 10) and the L. plantarum strain secreting sp3050-mIL-10 and sp0297-hElafin in a DSS-induced model of colitis. We administered daily either therapeutic SINERGY (DSS + Therapeutic SINERGY group), control yeast strain (DSS + Control Sc group), synthetic starter with control yeast and L. plantarum (DSS + Control starter), or therapeutic yeast consortia secreting mIL-10 and hElafin in response to eATP (DSS + Therapeutic Sc group). A healthy control group was also included.